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A B S T R A C T
Objectives: Following the public-health emergency of international concern (PHEIC) declared by the
World Health Organization (WHO) on 30 January 2020 and the recent outbreak caused by 2019 novel
coronavirus (2019-nCoV) [officially renamed severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2)] in China and 29 other countries, we aimed to summarise the clinical aspects of the
novelBetacoronavirus disease (COVID-19) and its possible clinical presentations together with suggested
therapeutic algorithms for patients who may require antimicrobial treatment.
Methods: The currently available literature was reviewed for microbiologically confirmed infections by
2019-nCoV or COVID-19 at the time of writing (13 February 2020). A literature search was performed
using the PubMed database and Cochrane Library. Search terms included ‘novel coronavirus’ or ‘2019-
nCoV’ or ‘COVID-19’.
Results: Published cases occurred mostly in males (age range, 8–92 years). Cardiovascular, digestive and
endocrine system diseases were commonly reported, except previous chronic pulmonary diseases [e.g.
chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis] that were surprisingly
underreported. Fever was present in all of the case series available, flanked by cough, dyspnoea,
myalgia and fatigue. Multiple bilateral lobular and subsegmental areas of consolidation or bilateral
ground-glass opacities were the main reported radiological features of 2019-nCoV infection, at least in
the early phases of the disease.
Conclusion: The new 2019-nCoV epidemic is mainly associated with respiratory disease and few
extrapulmonary signs. However, there is a low rate of associated pre-existing respiratory co-morbidities.
© 2020 Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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During December 2019, a novel Betacoronavirus provisionally
named 2019 novel coronavirus (2019-nCoV), and subsequently
officially renamed severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) by the International Committee on Taxonomy of
Viruses (ICTV), causing coronavirus disease 2019 (or COVID-19),
was associated with a cluster of respiratory tract infections in
Wuhan, Hubei Province, China [1] and has rapidly spread across
continents [2,3]. At 17 February 2020, according to surveillance by
the European Centre for Disease Prevention and Control (ECDC)
and the US Centers for Disease Control and Prevention (CDC) [2,3],
71 333 cases have been reported among 29 countries on five main
continents, and the number of deaths was 1775, almost all* Corresponding author. Present address: Department of Medical Sciences, Unit
of Infectious Diseases Unit, University of Turin, Turin, Italy.
E-mail address: tommaso.lupia89@gmail.com (T. Lupia).
http://dx.doi.org/10.1016/j.jgar.2020.02.021
2213-7165/© 2020 Published by Elsevier Ltd on behalf of International Society for Antim
(http://creativecommons.org/licenses/by-nc-nd/4.0/).occurring in China (N = 1770; with 1 case in each of the Philippines,
Hong Kong, France, Taiwan and Japan), with a currently reported
fatality rate of between 2–2.3% [2,3]. In this short report, we aimed
to summarise the clinical aspects of the novel Betacoronavirus
infection and its possible manifestations.
2. Materials and methods
A literature search was performed using the PubMed database
and Cochrane Library. Search terms included ‘novel coronavirus’
and ‘2019-nCoV’. The MeSH terms were ‘novel’ [all fields] AND
(‘coronavirus’ [MeSH terms] OR ‘2019-nCoV’ [all fields]) OR
‘COVID-19’ [all fields]). The defined search period from 30
November 2019 to 13 February 2020 was selected to compare
studies regarding the first outbreaks and findings. Given the nature
of the review, no ethical approval was required. The search was
performed by two investigators (SC and TL). A total of 225 studies
were identified (PubMed, n = 225; Cochrane Library, n = 0). Two
investigators then reviewed these articles, initially by title andicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license
T. Lupia et al. / Journal of Global Antimicrobial Resistance 21 (2020) 22–27 23abstract and then in detail, using a customised data abstraction
form. Studies were excluded if they had an incorrect subject matter
or were duplications or reviews. Only studies in English were
included. Twelve studies were identified for full-text review as
they contained original data.
3. Results
3.1. Patients characteristics
Most of the patients were male (Table 1) with an age range of 8–
92 years: interestingly, in the first period of this global epidemic
there have been few cases in young people aged <15 years [1,4–15].
Nevertheless, among known infected subjects outside of China, the
prevalence of males and the age distribution at the time of
diagnosis resemble those in the Chinese epidemic [4,6,15].
Although past medical histories were not always available [1,4–
15], hypertension was the most reported underlying condition
[1,4–15] in as many as 80% and 31.2%, respectively, in the case series
from Ren et al. [9] and Wang et al. [12]. Chen et al. [10] described
mostly cardiovascular and cerebrovascular diseases (40%) in their
population. Furthermore, Ren et al. [9] have reported underlying
chronic liver disease in their whole population (n = 5) and this
feature differs, at least so far, from the other cases of COVID-2019
[1,4–8,10–15].
Huang et al. [1] and Wang et al. [12] have shown a rate of
chronic obstructive pulmonary disease (COPD) of approximately
2% and 2.9%, respectively. Subsequently, Chen et al. [10] have
reported a rate of approximately 1% for respiratory system
diseases, different from an estimated COPD prevalence of between
1.2–8.9% in different regions of China [16]. Moreover, interstitial
lung disease, history of smoking, bronchiectasis or asthma were
underreported [1,4–15]. Diabetes was first mentioned by Huang
et al [1] and represented the main co-morbidity in their cohort (8/
41; 20%), and thereafter other authors [11,12] reported diabetes in
approximately 10% of subjects. Furthermore, among cases outside
Asia, Holshue et al. [4] have mentioned hypertriglyceridemia as the
sole chronic illness of the first US case of COVID-2019; on the other
hand, German cases [6] were overall healthy.
3.2. Signs and symptoms
Patients with confirmed 2019-nCoV infection mostly had
respiratory signs and symptoms [1,4–11]. Fever was reported in
all of the case series available, flanked by cough, mostly dry
(Table 1). Dyspnoea was not uncommon and was reported in the
entire cohort by Ren et al. (n = 5; 100%) [9]. A significant proportion
of patients complained of gastrointestinal symptoms such as
nausea, vomiting and diarrhoea, also appearing during the course
of illness, a distinct feature [1,4–15]: Holshue et al. [4] meticulously
described the evolution of the first US case, complaining first of
respiratory symptoms (i.e. dry cough) followed by abdominal
discomfort and self-limiting nausea, vomiting and diarrhoea. There
was myalgia or fatigue in 44–60% of Asian case series [1,9].
3.3. Chest radiographic abnormalities
Multiple bilateral lobular and subsegmental areas of consoli-
dation or bilateral ground-glass opacities were the main reported
radiological features of COVID-2019 [1,4–15]. In the 41 patients in
the case series reported by Huang et al. [1], all had plain chest
radiography (CXR) or computed tomography (CT) findings of
pneumonia. Although CT is the best method to define the extension
and typology of lung parenchyma involvement, CXR was mostly
employed as a first investigation, probably because of the
associated need to comply with infection control procedures [5].3.4. Laboratory abnormalities
Leukopenia was the most common abnormality [1,4–9],
reported in up to 63% of subjects in the study by Huang et al.
[1]. Thrombocytopenia occurred in the reports by Holshue et al. [4]
and Chen et al. [10] but is rarely reported in other series [1,5–15],
although low platelets counts were found in up to 45% of severe
acute respiratory syndrome coronavirus (SARS-CoV) and Middle
East respiratory syndrome coronavirus (MERS-CoV) infections
[17,18]. Nevertheless, abnormalities in hepatic [e.g. slight increase
in aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) levels] and muscle (e.g. slight increase in creatine kinase or
lactate dehydrogenase) enzymes were seen in early cases and later
reported (Table 1) [1,4–15]. As one might expect, C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR) were frequently
abnormal and, in contrast, most of the patients had normal
procalcitonin (PCT) levels at admission: in the cohort of Huang
et al. [1] up to 69% of patients had a PCT level of <0.1 ng/mL.
Interestingly in the case series of Wang et al. [12] a prolonged
prothrombin time was reported in approximately 58% of adults.
3.5. Complications and mortality
In one of the larger cohorts available by Huang et al. [1] with 41
patients, 4 (10%) had a superinfection and the risk increased with
the intensity of care [intensive care unit (ICU) care 31% vs. no ICU
care 0%; P = 0.0014], with almost all patients being treated with
empirical antibiotic coverage during the acute phase. Furthermore,
the risk of acute respiratory distress syndrome, with or without
specific bacterial superinfection, complicated the clinical course of
up to 29% of patients (12/41) [1]. In the same large cohort by Huang
et al. [1], in up to 12% of cases an increase in troponin I count
occurred, and five patients complained of an acute cardiac injury:
this finding requires further study to assess the heart tropism of
2019-nCoV and the cardiovascular risk of infected patients during
acute illness.
Chen et al. [10] reported a low rate (4%) of fungal isolates with a
clinical need for empirical antifungal treatment, with one case of
Candida glabrata, three cases of C. albicans and one case, more
important, of Aspergillus flavus isolation. Moreover, the authors
reported a lower rate of bacterial respiratory isolates, mostly
Acinetobacter baumannii and Klebsiella pneumoniae [10]; according
to that, microbiological data are poor to represent all of the 2019-
nCoV-infected population, and the follow-up time reported in the
literature is too short to define the real burden of post-viral
infectious complications.
The first wave of 2019-CoV has caused 1775 deaths despite the
severity of illness being mild in most of cases [1,4–9,12,14,15].
Wang et al. [19] have interestingly reviewed the underlying
diseases and demographic characteristics of deaths occurring in
the Wuhan epidemic and found that older adults (>70 years)
presented a shorter period between the first symptom and death
compared with younger persons [11.5 (range 6–19) days vs. 20
(range 10–41) days; P = 0.033], as previously reported for other
betacoronaviruses [17,18]: this confirms the increased severity in
the elderly for coronavirus illness [1,4–15]. Furthermore, according
to Wang et al. [19], 2019-CoV has developed a median period
between the symptomatic phase to death (median 14 days)
somewhat similar to MERS-CoV (median 14 days) and SARS-CoV
(median 17.4 days) [12,17,18] (Table 2).
4. Discussion
We are daily assessing the real extent of the 2019-CoV epidemic
and the scientific turmoil that is trying to keep up. We have
learned, at least scientifically, the lesson from previous epidemics
Table 1
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N/A Fever Cough N/A N/A N/A N/A N/A
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computed tomography; CTS,
corticosteroids; CXR, chest radiography; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; ICU, intensive care unit; IFN, interferon; LDH, lactate dehydrogenase; N/A, not available; PT, prothrombin
time.























Differences in pathogenicity and virulence of different coronaviruses currently reported in literature.
Main features 2019-nCoV (COVID-19) SARS MERS
Possible natural reservoir Bat Bat Bat
Mean incubation time in humans (days) 3–6 5 5
Origin Wuhan, China Guangdong Province, China Arabian Peninsula
Case number (period) 71 333 (as of 17 February 2020) 8098 (2002–2003) 2254 (2012–2013)
Type of illness Acute respiratory syndrome Severe acute respiratory syndrome Severe acute respiratory syndrome
Severity of symptoms Mild to moderate High High compared with SARS
Fatality rate (%) 2–2.3 >10 >35
2019-nCoV, 2019 novel coronavirus [officially renamed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)]; COVID-19, coronavirus disease 2019; SARS, severe
acute respiratory syndrome; MERS, Middle East respiratory syndrome.
Fig. 1. Positive reverse transcription PCR (RT-PCR) for 2019-nCoV (SAR-CoV-2) and clinical and/or radiological suspicion of bacterial superinfection. 3G, third-generation; CA,
community-acquired; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; CRE, carbapenem-resistant Enterobacteriaceae; MDR, multidrug-resistant; MRSA,
methicillin-resistant Staphylococcus aureus; PA, Pseudomonas aeruginosa; XDR, extensively drug-resistant.
26 T. Lupia et al. / Journal of Global Antimicrobial Resistance 21 (2020) 22–27of SARS-CoV and MERS-CoV [17,18,20,21]; therefore, we are
awaiting the true extent of this new disease with its features,
notably outside Chinese lands. The lack of specific clinical features,
the diagnostic microbiological challenge [e.g. reverse transcription
PCR (RT-PCR) on nasal or rhinopharyngeal swabs] along with the
2019-nCoV outbreak occurring during the delayed peak of the
seasonal influenza make the definition of COVID-19 a difficult task
[22]. On one hand, clinical symptoms such as high rate of fever and
respiratory symptoms resemble previous features of coronavirus
infection; on the other hand, systemic symptoms such as chills and
rigors seen, respectively, in 87% and in up to 73% of cases during
MERS-CoV and SARS-CoV epidemics, respectively, were an unusual
phenomenon among 2019-nCoV infection [17,18,20,21]. The usual
pattern of presentation of the novel coronavirus is quite unspecific
and is similar to many viral infections: most of the co-morbidities
in the past MERS-CoV epidemic had included cardiovascular
diseases (e.g. hypertension), history of smoking, and diabetes:
although the number of chronic illnesses is low and underreported
despite that, we are probably not that far to have a more precise
overview [17,18,20,21]. The high rate of radiological and clinically
suspicious pneumonia reported in the reviewed cohorts of patients
[1,4–15] call for a reflection, notably with a perspective view, on the
need for empirical antibiotic coverage in the setting of possible
bacterial superinfection, as in influenza virus outbreaks. As
reported in 2003 for the SARS-CoV epidemic, there was anincreased rate of methicillin-resistant Staphylococcus aureus
(MRSA) from 3.53% (3.53 cases per 100 admissions) during the
pre-SARS period to 25.3% during the SARS period (P < 0.001), with
an increased rate of ventilator-acquired pneumonia in ICUs, mostly
(47.1%) caused by MRSA [23]. Giving the number of common points
between 2019-nCoV and previous coronavirus infection, anti-
MRSA empirical treatment needs to be considered also with 2019-
nCoV to reduce the risk of superinfection. Therefore, assessing the
risk of MRSA and other difficult-to-treat bacterial superinfections
such as Pseudomonas aeruginosa and multidrug-resistant Gram-
negative bacilli colonisation, according to cardiovascular co-
morbidities, lung abnormalities or systemic diseases, the severity
of pneumonia and the risks of adverse events or drug-related
toxicity are crucial points for all suspected cases of 2019-nCoV. A
treatment algorithm is proposed and based on common risk
factors for MRSA and/or P. aeruginosa (Fig. 1). The risk of fungal co-
infection appears to be low [10], despite the fact that viral
infections such as influenza and a large number of classical risk
factors (e.g. haematological patients, solid-organ and haemato-
poietic stem cell transplant recipients, HIV patients) have been
described as a favourable environment for invasive fungal
infections, especially for invasive pulmonary aspergillosis [24].
Empirical antifungal treatment should only be considered in
critically patients with new pulmonary infiltrate superimposed on
a viral pneumonitis pattern, with the aim of confirming the
T. Lupia et al. / Journal of Global Antimicrobial Resistance 21 (2020) 22–27 27diagnosis by invasive techniques and/or the use of fungal
biomarkers. So far, data on the efficacy of specific antiviral
treatments are inconclusive, and the current series have reported a
wide range of management options [1,4–15]. Holshue et al. [4] have
resorted to compassionate use of remdesivir with a favourable
outcome; on the other hand, Chen et al. [10] in their population (99
patients) described antiviral treatment in 75 patients (76%) with a
median duration of 3 days (interquartile range, 3–6 days). In
conclusion from an infectious diseases perspective, based on the
lessons learned from the previous well-known coronavirus out-
breaks (e.g. MERS-CoV and SARS-CoV), we have to be ready for
further outbreaks and must focus our attention to the prompt
diagnosis of cases and infection control procedures with isolation
of suspected cases, and to anticipate those that may be the
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